Welcome to our dedicated page for Davita news (Ticker: DVA), a resource for investors and traders seeking the latest updates and insights on Davita stock.
DaVita Inc. (NYSE: DVA), a Fortune 500 leader in kidney care and dialysis services, maintains this dedicated news hub for stakeholders tracking its clinical advancements and financial performance. Access consolidated updates on earnings reports, strategic partnerships, and regulatory developments shaping the company’s position in global healthcare markets.
This resource serves investors and industry observers seeking timely insights into DaVita’s operational milestones, including innovations through DaVita Clinical Research and expansions of its integrated care network. Content spans press releases on treatment protocols, Medicare reimbursement updates, and collaborations with healthcare providers.
Key categories include quarterly financial disclosures, acquisitions in outpatient care, clinical trial outcomes, and quality improvement initiatives. Bookmark this page for streamlined access to verified updates about DaVita’s efforts to advance kidney disease management across 3,000+ U.S. dialysis centers.
DaVita (NYSE: DVA) announced the results of its modified Dutch auction tender offer, concluding on September 14, 2020. The company successfully purchased 7,981,679 shares at $88.00 each, totaling $702.4 million, representing approximately 6.5% of its outstanding stock. This share repurchase will be financed through cash on hand. The tender offer reflects DaVita’s commitment to enhancing shareholder value amidst ongoing challenges, including the COVID-19 pandemic.
DaVita Inc. (NYSE: DVA) announced the preliminary results of its modified Dutch auction tender offer for up to $1.0 billion of its common stock, which concluded on September 14, 2020. A total of 8,000,679 shares were tendered at or below $88.00 per share, leading to an expected purchase at this maximum price for a total cost of approximately $704 million. This represents about 6.6% of the company's outstanding shares. DaVita plans to finance these purchases using cash on hand, with final results pending confirmation by the depositary.
DaVita Inc. has appointed Shawn Guertin as a new independent director, effective Sept. 15. Guertin brings nearly 35 years of health care experience, including senior roles at Aetna, Inc. and Coventry Health Care. His expertise in financial strategy and managed care aims to strengthen DaVita's efforts in transforming kidney care. DaVita's Board now includes ten directors, maintaining a diversity of 40% racial/ethnic and gender representation. The company operates 2,795 outpatient dialysis centers in the U.S., serving over 205,300 patients.
In response to Hurricane Laura, DaVita Kidney Care opened its dialysis centers across Texas, Louisiana, Alabama, and Mississippi to all patients needing treatment, ensuring continuity of care. The company has coordinated care for nearly 700 evacuated dialysis patients and prepared 150 centers ahead of the hurricane, deploying essential resources. Patients are advised to adhere to local boil water advisories due to potential flooding. With a commitment to quality care, DaVita aims to support vulnerable patients during this emergency.
DaVita Clinical Research (DCR) has initiated two clinical trials to explore the impact of COVID-19 on patients with end stage kidney disease (ESKD) undergoing dialysis. The studies aim to investigate the role of COVID-19 antibodies in future infections and the relationship between genetic markers and the severity of COVID-19 symptoms. Approximately 524,000 individuals in the U.S. require dialysis, placing them at increased risk for severe COVID-19. Findings from these studies are expected to be published in early 2021, contributing valuable insights into the virus's effects on this vulnerable population.
DaVita Inc. (NYSE: DVA) announced a modified "Dutch auction" tender offer for up to $1.0 billion of its common stock. The share price will range from $77.00 to $88.00 and the offer will expire at midnight on September 14, 2020. This tender offer allows shareholders to specify tender amounts and prices, with DaVita determining the lowest acceptable price. The purchase will be financed with cash and potentially through borrowings. The company emphasizes that the offer is subject to specific conditions and is not a solicitation to sell shares.
DaVita has launched an expanded program named Bridge to Your Dreams to support clinical teammates pursuing nursing degrees. The initiative offers resources for patient care technicians and nurses to advance their education, covering tuition and related costs. Participants will receive guidance from academic advisors and success coaches, aiming to address educational barriers in nursing. With an expected shortfall of registered nurses, DaVita's program is crucial for cultivating a skilled workforce in kidney care. The company operates 2,795 dialysis centers in the U.S., serving over 205,300 patients.
DaVita Inc. (NYSE: DVA) has appointed Paula A. Price as an independent director, effective September 1, 2020. Ms. Price brings over 30 years of financial and operational experience from various industries, including her recent role as CFO of Macy's, Inc. She has a strong background in capital allocation and a commitment to healthcare innovation. With her addition, the DaVita Board now has nine directors, achieving over 75% diversity. Ms. Price will also serve on the Audit Committee, enhancing the board's expertise amid DaVita's focus on improving patient care.
DaVita Inc. (NYSE: DVA) has priced its $1.5 billion offering of senior notes due 2031 at a coupon of 3.750%. Closing is scheduled for August 11, 2020. Proceeds will redeem existing $1.5 billion senior notes due 2025, with the redemption set for August 21, 2020. The offering is conducted under Rule 144A and Regulation S, and is not registered under the Securities Act. The release includes forward-looking statements regarding the offering and its use of proceeds, along with risk factors related to market conditions and business impacts from COVID-19.
DaVita Inc. (NYSE: DVA) has announced a private offering of $1.5 billion in senior notes due 2031, subject to market conditions. The proceeds will be used to redeem all outstanding 5.000% senior notes due 2025, totaling $1.5 billion. A notice of redemption for the 2025 notes will be issued, contingent on the completion of the new offering. The notes are being offered under Rule 144A and Regulation S of the Securities Act. Risks include market conditions affecting the offering and ongoing impacts from the COVID-19 pandemic.
